IHP Therapeutics
- Biotech or pharma, therapeutic R&D
IHP was founded in 2020 to develop novel glycans for the targeted treatment of serious diseases. Our lead program, IHP-102, is a first-in-class, disease-modifying therapeutic for acute treatment of vaso-occlusive crises in patients with sickle cell disease (see BioCentury: “IHP: Creating an EpiPen for sickle cell disease”). IHP-102 is a novel complement and P-selectin inhibitor derived from heparin. It has demonstrated best-in-class preclinical data in two independent gold standard models. These data have been published in Haematologica and presented at the Foundation for SCD Research Annual Symposium, and at ASH (Dec 2022, Dec 2023 and Dec 2024). IHP has received scientific validation through 2 grants from NIH ($2.5M SBIR award and a HEAL award valued at $10M) as well as grant from DoD. IHP-102 is currently in IND-enabling studies, with IND filing possible next 12 months. Potential IHP-102 U.S. peak revenue is estimated >$1.2B/year and it could save U.S. healthcare >$3B/year.
Address
San CarlosCalifornia
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}